Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

NCT05690503 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.

NCT NCT05690503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05690503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Lead sponsor
New York State Psychiatric Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 20, 2023
Completion date
December 31, 2025
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive dysfunction, depressive symptoms, post-acute sequelae of covid-19